Audiologists in Marshall, MN Accepting Medicare
8 Audiologists found. Showing 1 - 8
 Hearing And Speech Center Audiologist Medicare: Medicare Enrolled Practice Location: 1424 East College Drive, Suite 200, Marshall, MN 56258 Phone: 507-532-2687 Fax: 507-337-1054 |
 Dr. Amber Landsman, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1424 E College Dr Ste 200, Marshall, MN 56258 Phone: 507-532-2687 |
Linda S Grong, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 300 S Bruce St, Marshall, MN 56258 Phone: 507-532-2687 Fax: 507-537-9190 |
Mrs. Lea M Williamson Audiologist Medicare: Not Enrolled in Medicare Practice Location: 300 S Bruce St, Marshall, MN 56258 Phone: 507-532-2687 Fax: 507-537-9190 |
Sharyce Marie Baartman, AU.D. Audiologist Medicare: May Accept Medicare Assignments Practice Location: 1424 E College Dr, Suite 200, Marshall, MN 56258 Phone: 507-532-2687 |
 Dr. Deric Wymer Peterson, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1424 E College Dr Ste 200, Marshall, MN 56258 Phone: 507-532-2687 |
Dr. Jessica Landsman, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 300 S Bruce St, Marshall, MN 56258 Phone: 507-532-9661 |
Mr. Robert Emerson Braun Audiologist Medicare: Not Enrolled in Medicare Practice Location: 706 Viking Dr, Marshall, MN 56258 Phone: 507-537-0708 |
News Archive
Sarcomatoid differentiation levels predict poor RCC survival
Research shows that the degree of sarcomatoid differentiation in patients with grade 4 renal cell carcinoma is not only associated with poor survival, but can also serve as an independent prognostic factor in these patients.
Actavis commences distribution of Methylphenidate Hydrochloride Extended-Release Capsules
Actavis Group, an international generic pharmaceuticals company, today announced that it recently received approval from the US Food & Drug Administration to market Methylphenidate Hydrochloride Extended-Release Capsules (LA) CII, USP, 20mg, 30mg, and 40mg. Actavis has first-to-file exclusivity on the 20mg, 30mg, and 40mg strengths.
Pro-Pharmaceuticals announces closure of $325,000 tranche of private placement
Pro-Pharmaceuticals, Inc., today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $4.4 million.
MU researcher exploring ways to meet the needs of young adults with autism
As the number of children diagnosed with autism spectrum disorders continues to rise, medical professionals have emphasized early diagnosis, intervention and treatment. However, less attention has been given to children with autism once they reach their teen years and adulthood.
› Verified 2 days ago
Chiropractors
Physical Therapists
Optometrists
Occupational Therapists
Audiologists
Speech-Language Pathologists
Podiatrists